Researchers Submit Patent Application, "Compositions For Blood Storage And Transfusions", for Approval (USPTO 20240156720).

A patent application has been submitted for a transdermal formulation that delivers active agents to treat diseases associated with elevated CD38 levels and decreased NAD+ levels. The formulation aims to reduce CD38 activity, increase NAD+ levels, and promote the activity of NAD+-dependent sirtuins. It can be used to treat inflammatory diseases, endothelial dysfunction, and age-related decline. The application also discusses a method for preparing blood samples with delayed onset or progression of storage lesions in red blood cells using a curcuminoid solution. Additionally, transdermal formulations are mentioned for delivering therapeutic agents for various chronic diseases and conditions. [Extracted from the article]